Liquidia (NASDAQ:LQDA) Trading Up 2.3%

Liquidia Co. (NASDAQ:LQDAGet Free Report) shares were up 2.3% during trading on Tuesday . The stock traded as high as $15.37 and last traded at $15.27. Approximately 62,039 shares changed hands during trading, a decline of 94% from the average daily volume of 977,694 shares. The stock had previously closed at $14.92.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Bank of America lifted their price target on shares of Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, December 21st. HC Wainwright lifted their target price on Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. LADENBURG THALM/SH SH increased their price target on Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of Liquidia in a research note on Monday. Finally, Wedbush reiterated an “underperform” rating and set a $3.00 price objective on shares of Liquidia in a research note on Thursday, December 21st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $21.00.

View Our Latest Report on LQDA

Liquidia Stock Down 0.2 %

The stock’s fifty day moving average price is $14.45 and its 200-day moving average price is $10.37.

Insiders Place Their Bets

In other news, General Counsel Russell Schundler sold 8,653 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.82, for a total value of $136,890.46. Following the completion of the sale, the general counsel now directly owns 488,087 shares of the company’s stock, valued at $7,721,536.34. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, General Counsel Russell Schundler sold 8,653 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46. Following the completion of the sale, the general counsel now owns 488,087 shares in the company, valued at approximately $7,721,536.34. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jason Adair sold 4,657 shares of Liquidia stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.81, for a total value of $73,627.17. Following the sale, the insider now directly owns 108,640 shares of the company’s stock, valued at $1,717,598.40. The disclosure for this sale can be found here. Insiders have sold a total of 54,605 shares of company stock valued at $862,904 over the last 90 days. 31.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently made changes to their positions in the stock. Citigroup Inc. bought a new position in Liquidia in the 1st quarter valued at about $592,000. BlackRock Inc. raised its position in Liquidia by 0.4% during the first quarter. BlackRock Inc. now owns 846,385 shares of the company’s stock valued at $6,077,000 after purchasing an additional 3,042 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Liquidia by 56.8% during the first quarter. Dimensional Fund Advisors LP now owns 74,307 shares of the company’s stock worth $534,000 after purchasing an additional 26,908 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in Liquidia during the first quarter worth $86,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Liquidia by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,659,082 shares of the company’s stock valued at $11,912,000 after purchasing an additional 47,161 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

(Get Free Report)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

See Also

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.